Dyax - Advancing Novel Biotherapeutics

Spotlight

Dyax Corp. Announces Expansion of Executive Roles Learn More

Dyax and Sigma-Tau Group Expand Agreement for KALBITOR ® (ecallantide) in Hereditary Angioedema Learn More

U.S. Patent Office Grants Dyax Corp.'s Request for an Interference with U.S. Patent No. 7,700,302 Issued to Adimab Learn More

Dyax Corp. Announces First Quarter 2011 Financial Results Learn More

See Important Safety Information and Full Prescribing Information including Boxed Warning and Medication Guide on www.KALBITOR.com

technology

At the core of our success is our powerful and proprietary drug discovery technology, phage display Learn More

Dyax Launches HAE Hope, an Online Resource     for Patients with Hereditary Angioedema
Learn More

FINANCIAL ASSISTANCE

Dyax Features Comprehensive Financial Assistance Program On Enhanced Product Website for KALBITOR® (ecallantide)
Learn More